A new kind of treatment for thrombocythemia: Anagrelide;Neues therapiekonzept bei thrombozythämie: Anagrelid

Onkologe

Volumn 12, Issue 12, 2006, Pages 1263-1274

  Griesshammer, M ^a   Thiele, J ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Anagrelide; Cytoreduction; Essential thrombocythemia; Leukemogenic potential; Reduction of complications

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; HYDROXYUREA;

CLINICAL STUDY; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; LEUKEMOGENESIS; MYELOPROLIFERATIVE DISORDER; REVIEW; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

EID: 33845669602     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-006-1147-y     Document Type: Review

References (35)

1. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92: 69-76
2. Birgegard G, Bjorkholm M, Kutti J et al. (2004) Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 89: 520-527
3. Cacciola RR, Francesco ED, Giustolisi R et al. (2004) Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia. Br J Haematol 126: 885-886
4. Cacciola RR, Cippola A, Di Francesco E et al. (2005) Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide. Am J Hematol 80: 81-83
5. Cortelazzo S, Viero P, Bellavita P et al. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332: 1132-1136
6. Fruchtman SM, Petitt RM, Gilbert HS et al. (2003) Anagrelide therapy significantly reduces disease related symptoms in patients with myeloproliferative disorders. Blood 102: 32A-33A
7. Fruchtman SM, Petitt RM, Gilbert HS et al. (2005) Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 29: 481-491
8. Griesshammer M (2006) Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 32: 372-380
9. Griesshammer, M Grunewald M, Michiels JJ (2003) Acquired thrombophilia in pregnancy: essential thrombocythemia. Semin Thromb Hemost 29: 205-212
10. Harrison CN, Campbell PJ, Buck G et al. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353: 33-45
11. Hong Y, Wang G, Del Arroyo AG et al. (2006) Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia 20: 1117-1122
12. Jurgens DJ, Moreno-Aspitia A, Tefferi A (2004) Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica 89: 1394-1395
13. Kiladjian JJ, Rain JD, Bernard JF et al. (2006) Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 32: 417-421
14. Knutsen H, Hysing J (2001) Anagrelide in primary thrombocythemia. Tidsskr Nor Laegeforen 121: 1478-1482
15. Kornblihtt LI, Vassallu PS, Heller P et al. (2002) Treatment of essential thrombocythemia with anagrelide: a ten-year experience. Medicina (B Aires) 62: 231-236
16. Laguna MS, Kornblihtt LI, Marta RF et al. (2000) Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide. Medicina (B Aires) 60: 448-452
17. Laguna MS, Kornblihtt LI, Marta RF et al. (2000) Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 6: 157-161
18. Lengfelder E, Hochhaus A, Kronawitter U et al. (1998) Should a platelet limit of 600x10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 100: 15-23
19. Lev PR, Marta RF, Vassallu P et al. (2002) Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide. Am J Hematol 70: 85-91
20. Mazur G, Wrobel T, Podolak-Dawidziak M et al. (2004) Anagrelide in the treatment of thrombocythemia essential (ET). Pol Arch Med Wewn 112: 1445-1450
21. Mazzucconi MG, Redi R, Bernasconi S et al. (2004) A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 89: 1306-1313
22. McCarty JM, Melone PD, Simanis JP et al. (2006) A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions. Exp Hematol 34: 87-96
23. Mills AK, Taylor KM, Wright SJ et al. (1999) Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 29: 29-35
24. Penninga E, Jensen BA, Hansen PB et al. (2004) Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 26: 335-340
25. Petitt RM, Silverstein MN, Petrone ME (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34: 51-54
26. Petrides PE, Beykirch MK, Trapp OM (1998) Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 61: 71-76
27. Shire Deutschland GmbH & Co. KG (2006) Fachinformation Xagrid® 0,5 mg Hartkapseln. Shire, Köln, S 1-3
28. Silverstein MN, Petitt RM, Solberg LA et al. (1988) Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 318: 1292-1294
29. Steurer M, Gastl G, Jedrzejczak WW et al. (2004) Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 101: 2239-2246
30. Storen EC, Tefferi A (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97: 863-866
31. Thiele J, Kvasnicka HM, Fuchs N et al. (2003) Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 88: 1130-1138
32. Thiele J, Kvasnicka HM, Ollig S et al. (2005) Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol 20: 1071-1076
33. Thiele J, Kvasnicka HM, Vardiman J (2006) Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol 19: 413-437
34. Wagstaff AJ, Keating GM (2006) Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs 66: 111-131
35. Yoon SY, Li CY, Mesa RA et al. (1999) Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 106: 682-688